Bristol Myers Expands NVIDIA Partnership for Life Sciences AI Supercomputer

Bristol Myers Squibb, a drugmaker focused on creating new medicines, is expanding its three-year partnership with Nvidia, a chipmaker providing artificial intelligence computing technology, to increase the power of its AI factory. As part of the expansion, Bristol Myers will deploy an Nvidia DGX SuperPOD equipped with DGX Vera Rubin NVL72 systems. The drugmaker said the installation would provide it with one of the most powerful AI supercomputers in the life-sciences industry.

The pharmaceutical industry is exploring whether AI could make the difficult drug-development process cheaper and easier. Bristol Myers said the system is being used to develop medicines more quickly, suggesting that the expanded computing capacity will support faster iteration and testing in its pipeline. The expansion may give Bristol Myers greater computing resources while further extending Nvidia's presence in life sciences.

Bristol Myers is not alone in adopting Nvidia's infrastructure for drug development. Nvidia has already established a separate partnership with Eli Lilly, a drugmaker participating in the pharmaceutical industry's push into AI computing. Amgen, another company that has adopted Nvidia's technology, has built an Nvidia supercomputer at a site in Iceland. These partnerships suggest Nvidia is expanding its relationships across the pharmaceutical sector, positioning the chipmaker as a central technology partner for the industry's AI-driven transformation of medicine development.

Bristol Myers' expansion of its Nvidia partnership reflects a broader shift in the pharmaceutical industry toward leveraging AI computing for drug development. The pharmaceutical sector has historically faced long timelines and high costs in bringing new medicines to market, and companies are testing whether AI-driven computing infrastructure can improve efficiency. By deploying one of the most powerful AI supercomputers in life sciences, Bristol Myers is positioning itself to accelerate its medicine-development pipeline while simultaneously deepening Nvidia's penetration in the pharma space.

The expansion also underscores Nvidia's success in converting pharmaceutical customers into longer-term partners. The presence of competing arrangements—Eli Lilly's separate partnership and Amgen's supercomputer installation in Iceland—demonstrates that Nvidia has established itself as the chipmaker of choice for life-sciences AI computing. These parallel deals suggest the pharmaceutical industry views Nvidia's infrastructure as critical to competitive drug development and that further deployments across the sector may follow.